Leflunomide for Maintenance of Remission in IgG4 Related Disease
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The study has been designed as a 12-month, open-label, randomized, controlled study comparing
the use of prednisone mono-therapy and prednisone and leflunomide combination therapy in
treating patients with IgG4-related disease.
Phase:
Phase 4
Details
Lead Sponsor:
Chinese PLA General Hospital
Treatments:
Immunoglobulin G Leflunomide Prednisolone Prednisone